Uric Acid News and Research

RSS

High uric acid precursor of obesity, metabolic syndrome

The relationship between uric acid and early cardiometabolic risk may precede obesity and the metabolic syndrome, show study findings.

20 Sep 2012

Hyperuricemia associated with more severe hepatic ATP depletion in response to fructose intake

Obese patients with type 2 diabetes who consume higher amounts of fructose display reduced levels of liver adenosine triphosphate (ATP)—a compound involved in the energy transfer between cells.

14 Sep 2012

UAB Center of Research Translation to improve health of patients with gout, hyperuricemia

The University of Alabama at Birmingham is establishing a Center of Research Translation to improve the health of an increasing number of patients with gout and hyperuricemia.

30 Aug 2012

Researchers create new type of biosensor that can detect glucose in saliva, tears

Researchers have created a new type of biosensor that can detect minute concentrations of glucose in saliva, tears and urine and might be manufactured at low cost because it does not require many processing steps to produce.

24 Aug 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

Study links procedural pain and detectable oxidative stress in neonates

There was a time when a belief was widely held that premature neonates did not perceive pain. That, of course, has been refuted but measurements of neonate pain tend to rely on inexact measures, such as alertness and ability to react expressively to pain sensations. Researchers at Loma Linda University reported in The Journal of Pain that there is a significant relationship between procedural pain and detectable oxidative stress in neonates.

2 Jul 2012

Exposure to phthalates may raise childhood obesity risk

Obese children have higher exposure to phthalates than nonobese children, suggest results presented at ENDO 2012 in Houston, Texas, USA, the annual meeting of The Endocrine Society.

27 Jun 2012

Study finds increase in incidence of gout and hyperuricemia in the U.S.

Researchers from Boston University School of Medicine (BUSM) have found that the incidence of gout and hyperuricemia (high uric acid levels) in the U.S. has risen significantly over the last 20 years and is associated with major medical disorders like hypertension and chronic kidney disease.

27 Jun 2012

New scoring system may better identify adolescents with metabolic syndrome

Researchers have developed a new scoring system that may better identify adolescents with the metabolic syndrome, a group at increased risk of later developing Type 2 diabetes and heart disease.

26 Jun 2012

Too much salt can damage blood vessels and lead to hypertension

A high sodium intake over a prolonged period of time is associated with increased vascular dysfunction, which may lead to hypertension, researchers report.

22 Jun 2012

Fructose may not be as bad for us as previously thought

A new study by researchers at St. Michael's Hospital suggests that fructose may not be as bad for us as previously thought and that it may even provide some benefit.

22 Jun 2012

Savient announces results from KRYSTEXXA Phase III trials on gout-related kidney disease

Savient Pharmaceuticals, Inc. announced that new data presented in an oral session at the European League Against Rheumatism (EULAR) 2012 congress showed that patients with refractory chronic gout (RCG) who also suffer from chronic kidney disease (CKD) responded to treatment with KRYSTEXXA (pegloticase) regardless of baseline CKD stage.

7 Jun 2012

Women and their loved ones are affected by gout: Survey

An online survey conducted by Red Hot Mamas North America, Inc. found that women and their loved ones are significantly affected by very painful bouts of gout, which they consider to be chronic and severe. Respondents indicated that although the debilitating pain associated with the condition affects quality of life, many individuals are prescribed medications meant to control the condition which they are not taking.

23 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

High fructose intake may increase risk of NFALD in obese people

Obese people who consume increased amounts of fructose, a type of sugar that is found in particular in soft drinks and fruit juices, are at risk for nonalcoholic fatty liver disease (NFALD) and more its more severe forms, fatty inflammation and scarring.

3 May 2012

Teens with high levels of uric acid at increased risk for high blood pressure

Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at the Johns Hopkins Children's Center.

30 Apr 2012

Takeda enters definitive agreement to acquire URL Pharma

Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.

12 Apr 2012